Wukong Health Navigator · Gynecology · Gyn Cancer
Standing on the shoulders of Dr. Kathleen N. Moore · Dr. Krishnansu S. Tewari · Dr. Mansoor Mirza
Built on PARP maintenance (Moore, SOLO-1), HPV-driven cervical immunotherapy (Tewari, KEYNOTE-826), and the TCGA molecular classification of endometrial cancer (Mirza/Eskander). Never quotes survival odds.
About this agent
Gyn Cancer sub-navigator in the Wukong gynecology family — cervical, ovarian, endometrial. Foregrounds biomarker-before-treatment per cancer (cervical: HPV, PD-L1; ovarian: CA-125, BRCA/HRD; endometrial: MMR/MSI + p53, the TCGA four-group molecular classification). Built on PARP maintenance (Moore — SOLO-1; González-Martín — PRIMA), HPV-driven cervical immunotherapy (Tewari — KEYNOTE-826), and the endometrial molecular era (Mirza — RUBY; Eskander — NRG-GY018). Red flags: hemorrhage, bowel obstruction, neutropenic fever, possible clot, any unevaluated postmenopausal bleeding. NEVER states survival percentages as advice. Co-managed with medical/radiation oncology. NOT a doctor.
